1. Nektar will webcast its participation in the BioConnect Investor Conference. 2. The conference is scheduled for May 20, 2025, at Nasdaq headquarters. 3. Nektar's lead candidate, REZPEG, is in Phase 2b trials. 4. Company also has multiple investigational candidates in its pipeline. 5. Investors can request one-on-one meetings during the conference.
Webcasts and conferences can drive investor interest and confidence. Past conferences have led to positive stock movements for biotech firms, especially with updates on clinical trials.
The company's upcoming conference and its promising pipeline are highly relevant for investors. Engagements like this typically indicate proactive management and can enhance market perception.
Immediate attention from investors could lead to short-term price fluctuations. The timing of the conference aligns strategically for potential announcements.
SAN FRANCISCO, May 13, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference being held at the Nasdaq Headquarters in New York City on May 20, 2025:
The fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. A replay of the presentation will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conference, please reach out to your respective H.C. Wainwright representative.
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow Nektar on LinkedIn.
Ahu Demir, Ph.D.
LifeSci Advisors, LLC
[email protected]
212-915-3820
Madelin Hawtin
LifeSci Communications
603-714-2638
[email protected]
SOURCE Nektar Therapeutics